(Q33681680)

28 July 2017

Assessing changes in relapse rates in multiple sclerosis (English)

1 reference

28 July 2017

0 references

4

Inmaculada B Aban

0 references

Gary R. Cutter

7

object named as

Gary R Cutter

0 references

author name string

Seidu Inusah

1

1 reference

28 July 2017

Maria P Sormani

2

1 reference

28 July 2017

Stacey S Cofield

3

1 reference

28 July 2017

Solomon K Musani

5

1 reference

28 July 2017

Vinodh Srinivasasainagendra

6

1 reference

28 July 2017

1 September 2010

1 reference

Multiple Sclerosis Journal

28 July 2017

1 reference

28 July 2017

16

1 reference

28 July 2017

12

1 reference

28 July 2017

1414-1421

1 reference

Clinical outcome measures in multiple sclerosis.

28 July 2017

1 reference

https://api.crossref.org/works/10.1177%2F1352458510379246

Oral fingolimod (FTY720) for relapsing multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458510379246

New diagnostic criteria for multiple sclerosis: guidelines for research protocols

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458510379246

A randomized study of two interferon-beta treatments in relapsing-remitting multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458510379246

Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458510379246

Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG)

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458510379246

A phase III trial of intramuscular recombinant interferon beta as treatment for exacerbating-remitting multiple sclerosis: design and conduct of study and baseline characteristics of patients. Multiple Sclerosis Collaborative Research Group (MSCRG).

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458510379246

Ingested IFN-alpha: results of a pilot study in relapsing-remitting MS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458510379246

Natalizumab plus interferon beta-1a for relapsing multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458510379246

A randomized, double-blind, placebo-controlled MRI study of anti-herpes virus therapy in MS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458510379246

Randomized study of once-weekly interferon beta-1la therapy in relapsing multiple sclerosis: three-year data from the OWIMS study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458510379246

Intrathecal Interferon Reduces Exacerbations of Multiple Sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458510379246

Systemic alpha-interferon therapy of multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458510379246

No difference in efficacy of two different doses of intravenous immunoglobulins in MS: clinical and MRI assessment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458510379246

Acyclovir treatment of relapsing-remitting multiple sclerosis. A randomized, placebo-controlled, double-blind study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458510379246

Interferon-alpha2a reduces MRI disease activity in relapsing-remitting multiple sclerosis. Norwegian Study Group on Interferon-alpha in Multiple Sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458510379246

A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458510379246

PRISMS-4: Long-term efficacy of interferon-beta-1a in relapsing MS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458510379246

Effects of oral glatiramer acetate on clinical and MRI-monitored disease activity in patients with relapsing multiple sclerosis: a multicentre, double-blind, randomised, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458510379246

B-cell depletion with rituximab in relapsing-remitting multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458510379246

Effect of laquinimod on MRI-monitored disease activity in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458510379246

Intravenous immunoglobulin in relapsing-remitting multiple sclerosis: a dose-finding trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458510379246

Treatment effects of monthly intravenous immunoglobulin on patients with relapsing-remitting multiple sclerosis: further analyses of the Austrian Immunoglobulin in MS study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458510379246

European/Canadian multicenter, double-blind, randomized, placebo-controlled study of the effects of glatiramer acetate on magnetic resonance imaging-measured disease activity and burden in patients with relapsing multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458510379246

Extended use of glatiramer acetate (Copaxone) is well tolerated and maintains its clinical effect on multiple sclerosis relapse rate and degree of disability. Copolymer 1 Multiple Sclerosis Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458510379246

Intravenous immunoglobulin treatment in multiple sclerosis. Effect on relapses.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458510379246

The efficacy of azathioprine in relapsing-remitting multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458510379246

A controlled trial of natalizumab for relapsing multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458510379246

A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458510379246

Randomised double-blind placebo-controlled study of interferon β-1a in relapsing/remitting multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458510379246

21 January 2018

Identifiers

DOI

10.1177/1352458510379246

1 reference

28 July 2017

1 reference